Cerus To Partner With Blood Centers Of America To Drive Expanded Access To Pathogen Reduction Technology For INTERCEPT Fibrinogen Complex Across Blood Center Membership

Cerus Corporation (NASDAQ:CERS) announced today that it has entered into a group purchasing agreement with Blood Centers of America (BCA), the largest blood supply cooperative in the U.S. BCA member blood centers produce approximately half of the U.S. platelet and cryoprecipitate supply. The agreement covers Cerus' entire INTERCEPT product line. Under this agreement, Cerus will partner with BCA to drive expanded access to pathogen reduction technology for platelets, plasma and pathogen reduced cryoprecipitated fibrinogen complex, commonly referred to as INTERCEPT Fibrinogen Complex, or IFC, across their blood center membership.